Literature DB >> 11511122

The immediate and long-term effect of optimal balloon angioplasty on the absolute coronary blood flow velocity reserve. A subanalysis of the DEBATE study. Doppler Endpoints Balloon Angioplasty Trial Europe.

J J Piek1, E Boersma, M Voskuil, C di Mario, E Schroeder, C Vrints, P Probst, B de Bruyne, C Hanet, E Fleck, M Haude, E Verna, V Voudris, H Geschwind, H Emanuelsson, V Mühlberger, H O Peels, P W Serruys .   

Abstract

BACKGROUND: There are limited data regarding the immediate and long-term effect of balloon angioplasty on the coronary flow reserve evaluated in a multicentre setting. METHODS AND
RESULTS: A total of 86 patients with one-vessel disease and normal left ventricular function were analysed before and after optimal balloon angioplasty (diameter stenosis <35%) and at 6-month follow-up. Coronary flow reserve was assessed with a Doppler guide wire. A low coronary flow reserve (<or=2.5) after PTCA, due to an increased baseline blood flow velocity, was encountered in 42 of the 86 patients (49%). Recurrence of angina and target lesion revascularization were more frequent in these patients than in patients with a coronary flow reserve >2.5 (46% vs 23% and 36% vs 16%, respectively; P<0.05) due to a trend towards restenosis (29% vs 16%; P=0.15) or a low coronary flow reserve at follow-up due to persistent elevated baseline blood flow velocity. Patients without restenosis showed a decrease or increase of coronary flow reserve during follow-up, determined by alterations of hyperaemic blood flow velocity.
CONCLUSIONS: Patients with an impaired coronary flow reserve directly after optimal balloon angioplasty showed a higher target lesion revascularization rate compared to patients with a coronary flow reserve >2.5. This patient group consists of patients prone to develop restenosis, while other patients are characterized by a persistently low coronary flow reserve, probably secondary to disturbed autoregulation and/or diffuse mild coronary atherosclerosis. Coronary flow reserve alterations in patients without restenosis were related to changes in hyperaemic blood flow velocity, suggesting that this phenomenon relates to epicardial remodelling. Copyright 2001 The European Society of Cardiology.

Entities:  

Mesh:

Year:  2001        PMID: 11511122     DOI: 10.1053/euhj.2000.2587

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

Review 1.  Assessing the Haemodynamic Impact of Coronary Artery Stenoses: Intracoronary Flow Versus Pressure Measurements.

Authors:  Valérie E Stegehuis; Gilbert Wm Wijntjens; Tadashi Murai; Jan J Piek; Tim P van de Hoef
Journal:  Eur Cardiol       Date:  2018-08

Review 2.  Prediction of Post Percutaneous Coronary Intervention Myocardial Ischaemia.

Authors:  Alda Huqi; Giacinta Guarini; Doralisa Morrone; Mario Marzilli
Journal:  Eur Cardiol       Date:  2016-12

3.  Myocardial perfusion imaging after transient balloon occlusion during percutaneous coronary interventions.

Authors:  Raed Aqel; Gilbert J Zoghbi; Luvenia W Bender; Johnny W Scott; Jon A Baldwin; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

Review 4.  Emerging, noninvasive surrogate markers of atherosclerosis.

Authors:  Samir N Patel; Venkataraman Rajaram; Sanjay Pandya; Benjamin M Fiedler; Charlotte J Bai; Rachel Neems; Matt Feinstein; Marshall Goldin; Steven B Feinstein
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

5.  Change in coronary blood flow after percutaneous coronary intervention in relation to baseline lesion physiology: results of the JUSTIFY-PCI study.

Authors:  Sukhjinder S Nijjer; Ricardo Petraco; Tim P van de Hoef; Sayan Sen; Martijn A van Lavieren; Rodney A Foale; Martijn Meuwissen; Christopher Broyd; Mauro Echavarria-Pinto; Rasha Al-Lamee; Nicolas Foin; Amarjit Sethi; Iqbal S Malik; Ghada W Mikhail; Alun D Hughes; Jamil Mayet; Darrel P Francis; Carlo Di Mario; Javier Escaned; Jan J Piek; Justin E Davies
Journal:  Circ Cardiovasc Interv       Date:  2015-06       Impact factor: 6.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.